Alzheimer’s disease

Adam's Biotech Scorecard Adam Feuerstein

STAT Plus: What’s next for Cassava Sciences, and Cartesian Therapeutics has a novel excuse for dodgy data

Biotech Elaine Chen and Matthew Herper

STAT Plus: FDA approves Eli Lilly’s early Alzheimer’s treatment

Biotech Jonathan Wosen

STAT Plus: Cassava Sciences collaborator charged with defrauding NIH in grants supporting its Alzheimer’s drug

D.C. Diagnosis Sarah Owermohle

STAT Plus: Senators push Medicare for a PET scan pay bump

The Readout Elaine Chen

STAT Plus: Vertex starts gene therapy Casgevy in five patients 

Health Jonathan Wosen

STAT Plus: Alzheimer’s risk gene APOE4 may cause a distinct form of the disease, study suggests

The Readout Elaine Chen

STAT Plus: Bernie Sanders targets ‘outrageously high price’ of Ozempic

The Readout Damian Garde

STAT Plus: Gas prices are hurting biotech